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Backgrounds: In a recent study by the CIBMTR (Blood
2013), stem cell transplantation (SCT) from an unrelated
donor with bidirectional 1-locus mismatch (1MM-Bi) or a
donor with 1-locus mismatch only in the graft-versus-host
(GVH) direction (1MM-GVH) was signiﬁcantly associated
with higher risks of overall mortality and severe acute
GVHD than SCT from an unrelated donor with an HLA-A,
-B, -C, -DRB1 8/8 allele match (0MM). However, SCT from
a donor with 1-locus mismatch only in the host-versus-
graft (HVG) direction (1MM-HVG) was not associated with
these risks. Therefore, selection of an unrelated donor
with 1MM-HVG was recommended when an 8/8-allele
matched donor is not available. However, the effect of
HLA-mismatch direction needs to be validated in other
populations.
Methods: We analyzed adult patients with leukemia or
myelodysplastic syndrome who received the ﬁrst allogeneic
SCT from an 8/8-allele matched or a 7/8-allele matched
unrelated donor between 2000 and 2011 in Japan. The effect
of 1MM-Bi (n¼1020), 1MM-GVH (n¼83), or 1MM-HVG
(n¼83) as compared with that of 0MM (n¼ 2570) was
analyzed after adjusting for other signiﬁcant variables. For
multiple comparisons, a value of P < 0.01 was used to
determine statistical signiﬁcance.
Results: The risk of overall mortality was signiﬁcantly
higher in the 1MM-Bi group than in the 0MM group
(hazard ratio [HR] 1.32, P<0.001), while there was no dif-
ference between the 1MM-GVH (HR 0.98, P ¼ 0.894) or
1MM-HVG group (HR 1.15, P¼0.368) and the 0MM group.
There were no signiﬁcant differences in overall survival
(OS) rates among the 1MM-Bi, 1MM-HVG, and 1MM-GVH
groups. Further, we observed no signiﬁcant differences in
the non-relapse mortality (NRM) and relapse rates between
the 0MM group and 1MM-GVH or 1MM-HVG group. The
risk of grade 3-4 acute GVHD was higher with a marginal
signiﬁcance in the 1MM-GVH group than in the 0MM
group (HR 1.85, P¼0.014). There was no signiﬁcant differ-
ence between the 1MM-HVG group and 0MM group (HR
1.25, P¼0.468).Conclusions: Although the risk of severe acute GVHD in
the 1MM-GVH group tended to be higher than that in the
0MM group, there was no signiﬁcant difference in the OS or
NRM rates. The 1MM-HVG group also showed an OS rate
comparable to that of the 0MM group. Unlike the conclusion
drawn by the CIBMTR study, in this study, there is no evidence
showing that an unrelated donor with 1MM-HVG should be
prioritized over one with 1MM-GVH in a Japanese cohort.56
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Background: Cord colitis syndrome is a new proposed
clinical entity characterized by late onset of watery diarrhea
after umbilical cord blood transplantation (UCBT), with
granulomatous inﬂammation and Paneth cell metaplasia,
and response to antibiotics.
Methods: We tested the hypothesis that recipients of UCBT
at our institution had late occurring colitis distinct from
colitis in other allograft recipients. We reviewed patients
who had colon biopsies between days 70-365 after UCBT and
marrow or peripheral blood allograft controls over a 5 years
period. Archival histological material was reviewed by the
pathologist who was blinded to any type of clinical infor-
mation. For each patient, a minimum of 32 serial sections of
colonic tissue were examined from different anatomical
areas. For all patients included in the analysis, we reviewed
immunosuppressive therapy treatments, anti-viral, antibac-
terial, anti-fungal and anti-parasite medications at the time
of the colon biopsy.
Results: Forty-ﬁve UCBT patients were matched with 45
allograft controls (Figure 1). The two groups were similar
with respect to age, intensity of conditioning regimen, sex,
and diagnosis. No differences were seen in use of anti-
bacterial and anti-fungal treatments, however patients
receiving UCBT were more likely to be receiving valacyclovir
than the control group (p¼0.003).There was a signiﬁcantly
higher incidence of aGVHD grade 3-4 in the UCBT cohort
compared to the controls (p¼0.01). Forty-three patients in
the UCBT group and 42 in the control group had evaluable
biopsy specimens. Watery diarrhea was the indication for
endoscopic biopsy in 10 UCBT and 11 controls while in the
remaining patients the indication to colon biopsy was either
abdominalpain, or nauseaoranorexia.Among theUCBTgroup,
themedian time of onset and duration of diarrheawas 96 days
(IQR85-105) and10days (IQR7-15), respectively. In the control
group the median time of onset of diarrhea was 88 days (IQR
84-105 days) while the median duration was 10 days (IQR 7-
15). Similar to thecontrolgroup,noUCBTrecipientwithwatery
diarrhea was treated with antibiotics and all responded to
systemic corticosteroids. No histological differenceswere seen
betweenUCBTand controls except for increased eosinophils in
the UCBT group (p¼0.04). Distorted mucosal architecture and
apoptotic crypt cells were the most common histological fea-
tures in both groups, while Paneth cell metaplasia and
epithelioid granulomas were rare ﬁndings (Figure 2).
Figure 1. Formation of study population
Figure 2
Histopathological results
All patients undergoing endoscopic
procedure n¼85
Patients with diarrhea n¼21
UCBT n¼43 n (%) Control Group
n¼42 n (%)
p-value UCBT n¼10
n (%)
Control Group
n¼11 n (%)
p-value
Individual features
Granulomas 1 (2) 1 (2) 0.99 0 1 (9) 0.99
Paneth cells 28 (65) 28 (67) 0.76 6 (60) 7 (64) 0.99
Mucosal distortion 28 (65) 28 (67) 0.76 6 (60) 8 (73) 0.66
Apoptosis 0.24 0.15
None 7 (16) 11 (26) 1 (10) 6 (55)
1 16 (37) 9 (21) 4 (40) 3 (27)
2 20 (47) 21 (50) 5 (50) 2 (18)
Increased eosinophils 10 (23) 3 (7) 0.04 0 1 (9) 0.99
Histologic Grade
Upper gut acute GVHD 33 (77) 28 (67) 0.48 9 (90) 8 (73) 0.99
Lower gut acute GVHD 0.86 0.86
None 14 (33) 14 (33) 4 (40) 6 (55)
Grade 1 13 (30) 14 (33) 3 (30) 3 (27)
Grade 2-3 16 (37) 13 (31) 3 (30) 2 (18)
Composite Pattern
Chronic Active Colitis 25 (58) 26 (62) 0.90 5 (50) 6 (55) 0.99
Chronic Inactive Colitis 6 (14) 4 (10) 1 (10) 2 (18)
Active Colitis 10 (23) 10 (24) 3 (30) 3 (27)
Unclassiﬁed 2 (5) 2 (4) 1 (10) 0
Abstracts / Biol Blood Marrow Transplant 20 (2014) S57eS71S58Conclusions: In this study population, colitis developing
after day 70 post transplant was diagnosed as acute GVHD
based on histopathology independent of the source of donor
hematopoietic cells. We could not identify the presence of a
cord colitis syndrome in our UCBT patients.57
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Background: DCB-T is an immediate alternative to URD-T for
patients with high-risk acute leukemia, MDS, or advanced
CML. Retrospective analyses in adult DCB-T recipients also
